Asset profile
Fazirsiran
RNA / oligonucleotide
Evidence outlook
Completed readouts not yet graded
This drug has completed mid- or late-stage studies whose evidence has not yet been graded on this platform. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
4 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 4 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Fazirsiran: this drug | Phase 3 | RNA / oligonucleotide | — | ||
| Alvelestat | Phase 2 | Small molecule | Neutrophil elastase | ||
| BEAM-302 | Phase 1/2 | Gene therapy / editing | — | ||
| WVE-006 | Phase 1/2 | RNA / oligonucleotide | — | ||
| KB408 | Phase 1 | Gene therapy / editing | — |
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2028 (1)
August 2028 (1)
What to watch
2029 (1)
January 2029 (1)
What to watch
2033 (1)
May 2033 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.